دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Issue Highlights page
doi : 10.1016/S0360-3016(21)02748-6
Volume 111, Issue 4, 15 November 2021, Pages A11-A12
Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma
Sarah A.MilgromMD?Richard L.BakstMD†Belinda A.CampbellMD‡§||
doi : 10.1016/j.ijrobp.2021.06.030
Volume 111, Issue 4, 15 November 2021, Pages 841-850
Arteriovenous Malformation: A Real Can of Worms
Jacob W.TrotterBS?John P.KirkpatrickMD, PhD?†
doi : 10.1016/j.ijrobp.2018.08.068
Volume 111, Issue 4, 15 November 2021, Pages 851-853
Blood Flow Out Must Equal Blood Flow In
Bruce E.PollockMD
doi : 10.1016/j.ijrobp.2021.03.040
Volume 111, Issue 4, 15 November 2021, Page 854
Manage Medically
Ching-JenChenMDJason P.SheehanMD, PhD
doi : 10.1016/j.ijrobp.2021.03.043
Volume 111, Issue 4, 15 November 2021, Pages 854-855
There Will Be Blood: Not All AVM Complications Are Due to Radiation
XuguangChenMD, PhDKristin J.RedmondMD, MPH
doi : 10.1016/j.ijrobp.2021.07.009
Volume 111, Issue 4, 15 November 2021, Page 855
The Influence of Patient–Provider Language Concordance in Cancer Care: Results of the Hispanic Outcomes by Language Approach (HOLA) Randomized Trial
Daniel M.SeibleMD*SoumaKunduBA†AlexaAzuaraBS*Daniel R.CherryBA†StevenArias†Vinit V.NalawadeMS*JonathanCruzBA†RolandoArreola*Maria ElenaMartinezPhD‡Jesse N.NodoraDrPH, MPH‡Douglas A.RahnMD*James D.MurphyMD, MS*
doi : 10.1016/j.ijrobp.2021.05.122
Volume 111, Issue 4, 15 November 2021, Pages 856-864
¡Aviso, Médicos!: The Effect of Direct Patient-Doctor Communication Cannot Be Overlooked
Raymond B.Mailhot VegaMD, MPH*David J.SherMD, MPH†
doi : 10.1016/j.ijrobp.2021.07.036
Volume 111, Issue 4, 15 November 2021, Pages 865-866
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry
Sophie R.de Mol van OtterlooMD?John P.ChristodouleasMD†Erwin L.A.BlezerPhD‡HafidAkhiatBSc†KevinBrownMA†AnanyaChoudhuryPhD§DaveEggertMS†Beth A.EricksonMD?Lois A.DaamenPhD‡CorinneFaivre-FinnPhD§Clifton D.FullerPhD#JoelGoldweinMD†ShaistaHafeezPhD??EmmaHallPhD††Kevin J.HarringtonFRCR??Uulke A.van der HeidePhD‡‡Robert A.HuddartPhD??Martijn P.W.IntvenPhD?Anna M.KirbyFRCR??SusanLalondrelleFRCR??ClaireMcCannPhD§§Bruce D.MinskyMD#StellaMookPhD?Marlies E.NoweePhD‡‡UweOelfkePhD??KristinaOrrlingPhD??Marielle E.P.PhilippensPhD?ArjunSahgalMD§§Christopher J.SchultzMD?Robbert J.H.A.TersteegPhD?Rob H.N.TijssenPhD?Alison C.TreeFRCR??Baukelienvan TriestPhD‡‡Chia-LinTsengMD§§William A.HallMD?1Helena M.VerkooijenPhD?‡1on behalf of theMR-Linac Consortium
doi : 10.1016/j.ijrobp.2021.07.003
Volume 111, Issue 4, 15 November 2021, Pages 867-875
Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study
DannyRischinMD*†MadeleineKingPhD‡LizbethKennyMBBS§?SandroPorcedduMD?#ChristopherWrattenMBBS??AndrewMacannMBChB††James E.JacksonMBBS‡‡MathiasBresselMSc§§AlanHerschtalPhD§§RichardFisherPhD§§TsienFuaMBBS??CharlesLinMBBS§ChenLiuMBBS??Brett G.M.HughesMBBS?##MargaretMcGrathMBBS???LachlanMcDowellMBBS†??JuneCorryMD†††‡‡‡
doi : 10.1016/j.ijrobp.2021.04.015
Volume 111, Issue 4, 15 November 2021, Pages 876-886
Have We Tipped the Balance in HPV-Associated Oropharyngeal Cancer?: The Patient-Experience Side of the De-Escalation Balance Scale
JolieRingashMD?†‡§
doi : 10.1016/j.ijrobp.2021.07.1693
Volume 111, Issue 4, 15 November 2021, Pages 887-889
Fear of Cancer Recurrence in Survivors of Human Papillomavirus–Associated Oropharyngeal Carcinoma
GeorginaCasswellMBChB, FRCR?KarlaGoughPhD†‡AllisonDrosdowskyMPH†MathiasBresselMSc§AndrewColemanMBBS?SudiShresthaPhD?IetaD'CostaMBBS?TsienFuaMBBS?AlbertTiongMBBS?ChenLiuMBBS?DannyRischinMD?¶LachlanMcDowellMBBS?¶
doi : 10.1016/j.ijrobp.2021.07.006
Volume 111, Issue 4, 15 November 2021, Pages 890-899
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial
ChristianBauesMD*†HelenGoergen†MichaelFuchsMD†‡JohannesRosenbrockMD*†ErenCelikMD*HansEichMD†§CarstenKobeMD†?Conrad-AmadeusVoltinMD?AndreasEngertMD†‡PeterBorchmannMD†‡SimoneMarnitzMD*†
doi : 10.1016/j.ijrobp.2021.07.1697
Volume 111, Issue 4, 15 November 2021, Pages 900-906
Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial
TingXuMD, PhD*Qing H.MengPhD†Susan C.GilchristMD, MS‡Steven H.LinMD, PhD*RuitaoLinPhD§TianlinXuMPH||Sarah A.MilgromMD¶Saumil J.GandhiMD*HaijunWuMD, PhD#YuZhaoMD??Juan C.Lopez-MatteiMD, FACC††RadheMohanPhD‡‡ZhongxingLiaoMD*
doi : 10.1016/j.ijrobp.2021.07.035
Volume 111, Issue 4, 15 November 2021, Pages 907-916
Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial
BoQiuMD?†DaQuanWangMD?†QiWenLiMD?†YingJiaWuBA?†SuPingGuoBA?†XiaoBoJiangMA?JianLanFangMA?JinYuGuoBA?FangJieLiuMD?†ChuChuMD?†BinWangPhD?LiChenPhD?JunZhangPhD?YiMeiLiuMA?YongHongHuMD?HuiLiuMD, PhD*†
doi : 10.1016/j.ijrobp.2021.06.032
Volume 111, Issue 4, 15 November 2021, Pages 917-925
3D Deep Learning Model for the Pretreatment Evaluation of Treatment Response in Esophageal Carcinoma: A Prospective Study (ChiCTR2000039279)
XiaoqinLiMS*†HanGaoMS‡§JianZhuPhD*†YongHuangMD*†YongbeiZhuPhD‡§WeiHuangMD*†ZhenjiangLiPhD*†KaiSunPhD‡?ZhenyuLiuPhD§¶#JieTianPhD‡§???BaoshengLiPhD, MD?†
doi : 10.1016/j.ijrobp.2021.06.033
Volume 111, Issue 4, 15 November 2021, Pages 926-935
The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis
Pim J.J.DamenMD*Tiuri E.KroeseMD*†Richardvan HillegersbergMD, PhD†EwoudSchuitPhD‡§MaxPetersMD, PhD*Joost J.C.VerhoeffMD, PhD*Steven H.LinMD, PhD?Peter S.N.van RossumMD, PhD*
doi : 10.1016/j.ijrobp.2021.07.1695
Volume 111, Issue 4, 15 November 2021, Pages 936-948
Radiation Therapy of Lymphatic Fistulae After Vascular Surgery in the Groin
Matthias G.HautmannPD, MD*BarbaraDietlPD, MD*LauraWagnerMD†‡FlorianZemanBS§OliverKölblMD*KarinPfisterMD†WilmaSchierlingPD, MD†
doi : 10.1016/j.ijrobp.2021.07.1696
Volume 111, Issue 4, 15 November 2021, Pages 949-958
Rapid Access Palliative Radiation Therapy Clinics: The Evidence Is There, but Where Are the Clinics? An Australian and New Zealand Perspective
DanielRoosBSc (Hons), DipEd, MBBS, MD, FRANZCR*MelissaJamesBSc, MBBS, FRANZCR†MinjaeLahMBBS, DipPallCare, FRANZCR‡KathyPopeMBBS (Hons), FRANZCR§AmyShorthouseBSc, BMed (Hons), FRANZCR?RamkumarGovindarajMBBS, MD, MPC, FRANZCR*TanyaHoltMBBS, FRANZCR¶
doi : 10.1016/j.ijrobp.2021.07.034
Volume 111, Issue 4, 15 November 2021, Pages 959-964
Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?
Nicholas GZaorskyMD, MS?†Daniel ESprattMD‡
doi : 10.1016/j.ijrobp.2021.07.1699
Volume 111, Issue 4, 15 November 2021, Pages 965-967
The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma
Alison L.CameronFRCR*Markus C.ElzePhD†MichelaCasanovaMD‡BirgitGeoergerMD§Mark N.GazeMD?VeroniqueMinard-ColinMD§KieranMcHughFRCR¶Rick R.van RijnMD#AnnaKelseyMRCS??HélèneMartelliPhD††HenryMandevilleMD (Res)‡‡GianniBisognoMD§§StephenLowisPhD??MilindRongheFRCPCH¶¶DanielOrbachMD##CecileGuizaniMSc†SabineFürst-RecktenwaldMD†Julia C.ChisholmPhD???Johannes H.M.MerksPhD†††‡‡‡on behalf of theEuropean Paediatric Soft Tissue Sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium
doi : 10.1016/j.ijrobp.2021.06.031
Volume 111, Issue 4, 15 November 2021, Pages 968-978
Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer
KaitlynLapenMD?ChristopherSabolMS*Amy L.TinMA†KathleenLynchMS, MPH‡AlyseKassaBA§XiaolinMabliRN*JohnFordRN*ElaineChaBS*Michael B.BernsteinMD*Lior Z.BraunsteinMD*OrenCahlonMD*Bobby M.DalyMD, MBA?KiriSandlerMD¶Susan A.McCloskeyMD, MSHS#Andrew J.VickersPhD†Atif J.KhanMD, MS*Erin F.GillespieMD*??
doi : 10.1016/j.ijrobp.2021.07.1692
Volume 111, Issue 4, 15 November 2021, Pages 979-991
What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
Sang-WonKimMD?†Won KyungChoMD‡Doo HoChoiMD, PhD‡HaeyoungKimMD, PhD‡OyeonChoMD, PhD§WonParkMD, PhD‡MisonChunMD, PhD§
doi : 10.1016/j.ijrobp.2021.07.005
Volume 111, Issue 4, 15 November 2021, Pages 992-998
Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees
HayeonKimPhD*Yongsook C.LeePhD†Stanley H.BenedictPhD‡BrandonDyerMD§MichaelPricePhD?YiRongPhD¶AnanthRaviPhD#EricLeungMD??SushilBeriwalMD, MBA*Mark E.BernardMD††JyotiMayadevMD‡‡Jessica R.L.LeifMS§§YingXiaoPhD??
doi : 10.1016/j.ijrobp.2021.06.019
Volume 111, Issue 4, 15 November 2021, Pages 999-1010
Definitive, nonsurgical management of gynecologic malignancies involves external beam radiation therapy (EBRT) and/or brachytherapy (BT). Summation of the cumulative dose is critical to assess the total biologic effective dose to targets and organs at risk. Cumulative dose calculation from EBRT and BT can be performed with or without image registration (IR) and biologic dose summation. Among these dose summation strategies, linear addition of dose-volume histogram (DVH) parameters without IR is the global standard for composite dose reporting. This approach stems from an era without image guidance and simple external beam and brachytherapy treatment approaches. With technological advances, EBRT and high-dose-rate BT have evolved to allow for volume-based treatment planning and delivery. Modern conformal therapeutic radiation involves volumetric or intensity modulated EBRT, capable of simultaneously treating multiple targets at different specified dose levels. Therefore, given the complexity of modern radiation treatment, the linear addition of DVH parameters from EBRT and high-dose-rate BT is challenging to represent the combined dose distribution. Deformable image registration (DIR) between EBRT and image guided brachytherapy (IGBT) data sets may provide a more nuanced calculation of multimodal dose accumulation. However, DIR is still nascent in this regard, and needs further development for accuracy and efficiency for clinical use. Biologic dose summation can combine physical dose maps from EBRT and each IGBT fraction, thereby generating a composite DVH from the biologic effective dose. However, accurate radiobiologic parameters are tissue-dependent and not well characterized. A combination of voxel-based DIR and biologic weighted dose maps may be the best approximation of dose accumulation but remains invalidated. The purpose of this report is to review dose summation strategies for EBRT and BT, including conventional equivalent dose in 2-Gy fractions dose summation without image registration, physical dose summation using 3-dimensional rigid IR and DIR, and biologic dose summation. We also provide general clinical workflows for IGBT with a focus on cervical cancer.
FLASH Dose Rate Helium Ion Beams: First In Vitro Investigations
ThomasTessonnierPhD*1StewartMeinPhD*†‡§||1Dietrich W.M.WalshPhD*†‡§||1NoraSchuhmacher*†‡§||HansLiewMSc†‡§||¶RainerCeePhD*MichaelGalonskaPhD*StefanScheloskePhD*ChristianSchömersPhD*UliWeberPhD#StephanBronsPhD*JürgenDebusMD, PhD‡§||¶ThomasHabererPhD*AmirAbdollahiMD, PhD*†‡§||AndreaMairaniPhD*??2IvanaDokicPhD*†‡§||2
doi : 10.1016/j.ijrobp.2021.07.1703
Volume 111, Issue 4, 15 November 2021, Pages 1011-1022
Evaluation of Motion Compensation Methods for Noninvasive Cardiac Radioablation of Ventricular Tachycardia
Michael T.PrusatorPhD?PamelaSamsonMD*JochenCamminPhD†CliffordRobinsonMD*PhillipCuculichMD‡Nels C.KnutsonPhD*S. MurtyGodduPhD*KaitlinMooreBS‡Geoffrey D.HugoPhD*
doi : 10.1016/j.ijrobp.2021.06.035
Volume 111, Issue 4, 15 November 2021, Pages 1023-1032
First-In-Human Validation of CT-Based Proton Range Prediction Using Prompt Gamma Imaging in Prostate Cancer Treatments
JonathanBertholdMSc?†ChirasakKhamfongkhrueaMSc?‡JohannesPetzoldtPhD§JuliaThiele?TobiasHölscherMD?PatrickWohlfahrtPhD?†NilsPetersMSc?†AngelinaJostBSc?#ChristianHofmannPhD??GuillaumeJanssensPhD§JulienSmeetsPhD§ChristianRichterPhD?†?††
doi : 10.1016/j.ijrobp.2021.06.036
Volume 111, Issue 4, 15 November 2021, Pages 1033-1043
Hyperpolarized 129Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans
Leith J.RankinePhD?†ZiyiWangPhD‡Chris R.KelseyMD§EliannaBierMS‡BastiaanDriehuysPhD†‡?Lawrence B.MarksMD?Shiva K.DasPhD?
doi : 10.1016/j.ijrobp.2021.07.002
Volume 111, Issue 4, 15 November 2021, Pages 1044-1057
To present a methodology to use pulmonary gas exchange maps to guide functional avoidance treatment planning in radiation therapy (RT) and evaluate its efficacy compared with ventilation-guided treatment planning.
Interprofessional Image Verification Workshop for Physician and Physics Residents: A Multi-Institutional Experience
LauraPadillaPhD*Jay W.BurmeisterPhD†Omer LeeBurnettMD‡Elizabeth L.CovingtonPhD‡Robert B.DenMD§Michael M.DominelloDO†Kevin L.DuMD, PhD?Paulina E.GalavisPhD?StephanieJunellPhD¶JennaKahnMD¶MonicaKishoreMS¶KarenMooneyPhD§Nitai D.MukhopadhyayPhD#Matthew T.StudenskiPhD??Raphael L.YechieliMD??Emma C.FieldsMD*
doi : 10.1016/j.ijrobp.2021.07.1706
Volume 111, Issue 4, 15 November 2021, Pages 1058-1065
In Vivo Imaging of the Microglial Landscape After Whole Brain Radiation Therapy
Brendan S.WhitelawPhD?SeanTannyPhD†Carl J.JohnstonPhD‡Ania K.MajewskaPhD?§#M. KerryO'BanionMD, PhD*?#BrianMarplesPhD†
doi : 10.1016/j.ijrobp.2021.07.038
Volume 111, Issue 4, 15 November 2021, Pages 1066-1071
Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors
KonstanzeLettau*†ShayanKhozooeiMSc*†CorinnaKosnopfelPhD‡DanielZipsMD*†BirgitSchittekPhD§MahmoudToulanyPhD*†
doi : 10.1016/j.ijrobp.2021.06.021
Volume 111, Issue 4, 15 November 2021, Pages 1072-1087
Multifunctional Y-box binding protein-1 (YB-1) is highly expressed in different human solid tumors and is involved in various cellular processes. DNA damage is the major mechanism by which radiochemotherapy (RCT) induces cell death. On induction of DNA damage, a multicomponent signal transduction network, known as the DNA damage response, is activated to induce cell cycle arrest and initiate DNA repair, which protects cells against damage. YB-1 regulates nearly all cancer hallmarks described to date by participating in DNA damage response, gene transcription, mRNA splicing, translation, and tumor stemness. YB-1 lacks kinase activity, and p90 ribosomal S6 kinase and AKT are the key kinases within the RAS/mitogen-activated protein kinase and phosphoinositide 3-kinase pathways that directly activate YB-1. Thus, the molecular targeting of ribosomal S6 kinase and AKT is thought to be the most effective strategy for blocking the cellular function of YB-1 in human solid tumors. In this review, after describing the prosurvival effect of YB-1 with a focus on DNA damage repair and cancer cell stemness, clinical evidence will be provided indicating an inverse correlation between YB-1 expression and the treatment outcome of solid tumors after RCT. In the interest of being concise, YB-1 signaling cascades will be briefly discussed and the current literature on YB-1 posttranslational modifications will be summarized. Finally, the current status of targeting the YB-1 axis, especially in combination with RCT, will be highlighted.
In Regard to Lee et al.
TakahisaEriguchiMDAtsuyaTakedaMD, PhDYutoKimuraMSNaokoSanukiMD, PhD
doi : 10.1016/j.ijrobp.2021.07.012
Volume 111, Issue 4, 15 November 2021, Pages 1088-1089
In Reply to Erguchi et al.
PercyLeeMDAnTaiPhDX. AllenLiPhD
doi : 10.1016/j.ijrobp.2021.07.015
Volume 111, Issue 4, 15 November 2021, Pages 1089-1090
Reoxygenation With Fractionated Radiation Therapy in Clinical Practice
SanthanamSundarMRCP, FRCRPaulSymondsMD, FRCR
doi : 10.1016/j.ijrobp.2021.07.013
Volume 111, Issue 4, 15 November 2021, Pages 1090-1091
In Regard to Goodman et al.
Malcolm D.MattesMDShaunaCampbellDONehaVapiwalaMDDaniel W.GoldenMD, MHPECurtilandDevilleJrMDThomasEichlerMDTrevor J.RoyceMD, MS, MPH
doi : 10.1016/j.ijrobp.2021.07.014
Volume 111, Issue 4, 15 November 2021, Pages 1091-1092
In Regard to Chowdhary et al.
Varun KumarChowdhryMD
doi : 10.1016/j.ijrobp.2021.07.1718
Volume 111, Issue 4, 15 November 2021, Pages 1092-1093
In Reply to Chowdhry
MuditChowdharyMDSinéadO'BryantBSNehaVapiwalaMDOsamaMohamadMD, PhDTrevor J.RoyceMD, MS, MPH
doi : 10.1016/j.ijrobp.2021.07.1719
Volume 111, Issue 4, 15 November 2021, Page 1093
Expression of Editorial Concern: Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457-e462.
Anthony L.ZietmanMD
doi : 10.1016/j.ijrobp.2021.08.016
Volume 111, Issue 4, 15 November 2021, Page 1094
